SWOG
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1956-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.swog.org
S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer
- First Posted Date
- 2008-11-18
- Last Posted Date
- 2020-03-06
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 85
- Registration Number
- NCT00792701
- Locations
- 🇺🇸
Tibotec Therapeutics - Division of Ortho Biotech Products, LP, Marysville, California, United States
🇺🇸Valley Medical Oncology Consultants - Pleasanton, Pleasanton, California, United States
🇺🇸Sutter Cancer Center at Roseville Medical Center, Roseville, California, United States
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
- Conditions
- Gallbladder CancerExtrahepatic Bile Duct Cancer
- Interventions
- Radiation: 3-dimensional conformal radiation therapyRadiation: intensity-modulated radiation therapy
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2018-04-09
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 105
- Registration Number
- NCT00789958
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Memorial Sloan-Kettering Cancer Center - Rockville Centre, Rockville Centre, New York, United States
🇺🇸Great Falls Clinic - Main Facility, Great Falls, Montana, United States
S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00788580
S0000B: Vitamin E and/or Selenium in Preventing Cataract and Age-Related Macular Degeneration in Men on SELECT SWOG-S0000
- Conditions
- Macular DegenerationCataract
- Interventions
- First Posted Date
- 2008-11-02
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 13475
- Registration Number
- NCT00784225
- Locations
- 🇺🇸
Harvard Medical School, Boston, Massachusetts, United States
S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo
- Conditions
- Breast CancerChemotherapeutic Agent ToxicityNeuropathyNeurotoxicityFatigue
- Interventions
- Dietary Supplement: acetyl-L-carnitine hydrochlorideOther: placebo
- First Posted Date
- 2008-10-20
- Last Posted Date
- 2017-08-14
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 437
- Registration Number
- NCT00775645
- Locations
- 🇺🇸
St. James Healthcare Cancer Care, Butte, Montana, United States
🇺🇸Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana, United States
🇺🇸Genesys Hurley Cancer Institute, Flint, Michigan, United States
S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2020-03-06
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 61
- Registration Number
- NCT00770120
- Locations
- 🇺🇸
Christine LaGuardia Phillips Cancer Center at Wellmont Holston Valley Medical Center, Kingsport, Tennessee, United States
🇺🇸USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸Doctors Hospital at Ohio Health, Columbus, Ohio, United States
S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: rituximabRadiation: tositumomab
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 87
- Registration Number
- NCT00770224
- Locations
- 🇺🇸
Doctors Hospital at Ohio Health, Columbus, Ohio, United States
🇺🇸CCOP - Columbus, Columbus, Ohio, United States
🇺🇸Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
- Conditions
- Lymphoma
- Interventions
- Biological: rituximabProcedure: autologous-autologous tandem hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00723658
- Locations
- 🇺🇸
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States
🇺🇸St. Joseph Mercy Oakland, Pontiac, Michigan, United States
🇺🇸Sparrow Regional Cancer Center, Lansing, Michigan, United States
S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000
- Conditions
- Precancerous ConditionColorectal Cancer
- Interventions
- First Posted Date
- 2008-06-27
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 8094
- Registration Number
- NCT00706121
- Locations
- 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- Biological: cetuximabProcedure: therapeutic surgical procedureRadiation: radiation therapy
- First Posted Date
- 2008-05-29
- Last Posted Date
- 2018-05-18
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 83
- Registration Number
- NCT00686166
- Locations
- 🇺🇸
Cancer Center of Kansas-Independence, Independence, Kansas, United States
🇺🇸Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
🇺🇸USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States